Distinct immune signatures in chronic lymphocytic leukemia (CLL) and Richter’s syndrome (RS).

Authors

null

Yucai Wang

Mayo Clinic, Rochester, MN

Yucai Wang , Sutapa Sinha , Haidong Dong , Charla Secreto , Timothy Call , Sameer Ashok Parikh , Jose Francisco Leis , Karen Rech , Andew L. Feldman , Saad Kenderian , Neil E. Kay , Stephen M. Ansell , Rong He , Wei Ding

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Sub Track

Chronic Lymphocytic Leukemia (CLL) and Hairy Cell

Citation

J Clin Oncol 36, 2018 (suppl; abstr 7524)

DOI

10.1200/JCO.2018.36.15_suppl.7524

Abstract #

7524

Poster Bd #

161

Abstract Disclosures

Similar Posters

First Author: Maud Rijnders

Poster

2017 ASCO-SITC Clinical Immuno-Oncology Symposium

Correlation of T-cell infiltration and clonality with PD-L1 expression in soft tissue sarcomas.

Correlation of T-cell infiltration and clonality with PD-L1 expression in soft tissue sarcomas.

First Author: Seth Pollack

Poster

2021 ASCO Annual Meeting

Differentiated activity profile for the PD-1 inhibitor balstilimab.

Differentiated activity profile for the PD-1 inhibitor balstilimab.

First Author: Cailin Joyce

Poster

2019 ASCO-SITC Clinical Immuno-Oncology Symposium

T-cell lymphoma secondary to checkpoint inhibitor (CPI) used for other malignancies.

T-cell lymphoma secondary to checkpoint inhibitor (CPI) used for other malignancies.

First Author: Kartik Anand